文献速递膀胱癌与上尿路尿路上皮癌

膀胱癌长期肿瘤学结局:一项25年随访的基于人群研究

Long-term oncological outcomes of bladder cancer: a population-based study with a 25-year follow-up.
PubMed 文献 · BJU Int · 2025-08-07

该前瞻性多中心人群队列纳入1995–1996年瑞典斯德哥尔摩新诊断膀胱癌患者526例(NMIBC 396例),随访25年。低危NMIBC、高危NMIBC和MIBC的癌特异性死亡率分别为3%、26%和71%;高危NMIBC中22%进展为MIBC、17%进展为转移性疾病,T1患者37%死于膀胱癌。

要点

  • 高危NMIBC患者自初诊起25年内持续存在癌特异性死亡风险,T1患者尤为突出。
  • 高危NMIBC随访期间22%进展为MIBC、10%淋巴结进展、17%转移。
  • MIBC接受手术者5年癌特异性死亡率为39%,提示需优化高危T1且预期寿命长患者的治疗。

核心结论

  • 高危NMIBC患者自初诊起25年内持续存在癌特异性死亡风险,T1肿瘤患者更突出。
  • 研究提示对选择性高危T1且预期寿命长、进展风险高的患者应给予最佳治疗。

研究设计与样本

  • 前瞻性多中心人群队列研究,纳入1995–1996年瑞典斯德哥尔摩新诊断膀胱癌患者共526例,其中NMIBC 396例。
  • 主要结局为癌特异性死亡率,分别按低级别NMIBC、高级别NMIBC和MIBC分析,采用竞争风险累积发生率评估生存结局。

主要发现

  • 低级别NMIBC、高级别NMIBC和MIBC的癌特异性死亡率分别为3%、26%和71%。
  • 102例T1患者中37%在25年随访期间死于膀胱癌。
  • 178例高级别NMIBC中22%进展为MIBC、10%淋巴结进展、17%转移。
  • 接受手术的MIBC患者5年癌特异性死亡率为39%。

临床怎么用

  • 对高危NMIBC尤其是T1且预期寿命长的患者,应重视长期随访与最佳治疗选择。

局限性

  • 研究建立于30年前,可能影响结果对当前临床实践的适用性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To describe the oncological outcomes for patients with newly diagnosed bladder cancer, as long-term oncological outcomes and natural history of different initial subtypes of diagnoses of bladder cancer are understudied. PATIENTS AND METHODS: This was a prospective, multicentre population-based cohort study, where newly diagnosed patients with bladder cancer from 1995 to 1996 in Stockholm County, Sweden were followed. The primary outcome was cancer-specific mortality (CSM), separately analysed for low-grade non-muscle-invasive bladder cancer (NMIBC Low), high-grade non-muscle-invasive bladder cancer (NMIBC High), and muscle-invasive bladder cancer (MIBC). We used cumulative incidence with competing risk to assess survival outcomes. RESULTS: In total, 526 patients were included, 396 had NMIBC. Out of 102 patients with T1, 37% died of bladder cancer during the 25-year follow-up. The rate of CSM for NMBIC Low was 3%, NMIBC High 26%, and MIBC 71%, respectively. For the operated patients with MIBC, the 5-year CSM was 39%. Of the 178 patients with NMIBC High, 22% progressed to MIBC, 10% had lymph node progression, and 17% progressed to metastatic disease during the follow-up. The main limitation of the study is that it was established 30 years ago. CONCLUSION: In this population-based study, we found that patients with NMIBC High had a persistent risk of CSM up to 25 years from the initial diagnosis, more specifically in patients with T1 tumours. The study demonstrates the importance for optimal treatment for selective high-risk T1 patients with long life expectancy, and high risk of progression.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Dey L, Rautiola J, Akre O, et al. Long-term oncological outcomes of bladder cancer: a population-based study with a 25-year follow-up. BJU Int. 2025. PMID: 40776485. doi:10.1111/bju.16883

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。